Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
SongXJiaHJiangYWangLZhangYMuYet alAnti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 diabetes Mellitus: a meta-analysis
Cardiovascular outcomes trials demonstrate favourable safety profiles with some agents reducing major adverse cardiovascular events
Do GLP-1 drugs really lower inflammation
GLP-1 receptor agonists (such as semaglutide and tirzepatide) are FDA-approved for Type 2 diabetes and chronic weight management
Dogs and pigs were also used in pharmacology studies to assess cardiovascular and gastrointestinal effects
Sun S, Hisland L, Grenet G et al (2021) Reappraisal of the efficacy of intensive glycaemic control on microvascular complications in patients with type 2 diabetes: a meta-analysis of randomised control-trials
US$ 28.32
US$ 23.35
US$ 28.22
US$ 29.85
US$ 24.68
